9月20日，2025年湖北省中医药学会眼科专业委员会第十二次学术会议暨中医特色疗法治疗内外障眼病 学习班在恩施市举行。会议由湖北省中医药学会、湖北时珍实验室联合主办，湖北省中医药学会眼科专 业委员会、湖北省中医院、恩施州中心医院共同承办。 本次年会以"传承创新·融通致远·守护光明"为主题，旨在传承和弘扬中医药文化，搭建高水平学术交流 平台，推动眼科医学发展。中华中医药学会眼科专业委员会主委亢泽峰教授，爱尔眼科医院集团湖北省 区、鄂豫大区总院长邢怡桥教授，爱尔眼科医院集团湖北省区副总院长、恩施州中心医院湖北省眼遗传 病临床研究中心主任李拓教授等多位全国知名专家分享了最新研究成果与临床经验。 会议还创新设置"睛明论剑·宗师鉴方"环节，由来自宜昌、荆州、荆门等多地的眼科专家代表展示典型 病例与治疗技术，现场为一名64岁的眼疾患者辩证施治、现场开方。现场多位专家教授参与现场点评和 讨论。 此外，会议还设置了"悟经典—中医眼科知识竞赛"环节，通过现场竞答形式，考察参会者对中医经典文 献、眼科理论基础及临床应用的理解，激发学习热情，提升专业素养。在"勤学技—新技术交流"部分， 多位眼科专家就《平衡免疫，最佳守护》《近视管 ...

Core Insights - A groundbreaking achievement in treating Type 1 diabetes mellitus (T1DM) has been reported by Professor An Chiying and her team at Shenzhen Hengsheng Hospital, where 24 patients have successfully discontinued insulin therapy through holistic integrative medicine (HIM) since June 2024, with the longest insulin-free duration reaching 14 months [1][5] Group 1: Treatment Methodology - The HIM model combines traditional Chinese medicine (TCM), orthomolecular medicine, functional medicine, and lifestyle medicine, focusing on immune blockade and metabolic balance, alongside precision remote digital healthcare to restore islet function [2][3] - The treatment protocol involves multidisciplinary collaboration, including precision diagnostics, immune regulation through molecular nutrition and TCM, metabolic repair via acupuncture and herbal medicine, and precision monitoring using artificial intelligence for personalized treatment adjustments [3] Group 2: Clinical Outcomes - Over a two-year observation period, 70 T1DM patients were treated, with 24 patients (34%) completely discontinuing insulin use while maintaining stable blood glucose levels (HbA1c < 7%) and showing significant recovery of islet function as indicated by C-peptide testing [5][6] - Patients diagnosed early with T1DM and having a C-peptide level above 0.5 ng/ml can stop insulin, while those with lower islet function can significantly reduce insulin dosage once blood glucose levels are stabilized [6] Group 3: Expert Evaluation and Implications - Academician Fan Daiming of the Chinese Academy of Engineering praised the results, stating that they challenge the traditional view of lifelong medication for T1DM and highlight the potential of HIM as a new clinical treatment paradigm [7] - The global T1DM patient population is approximately 9 million, with traditional treatment costs exceeding RMB 10,000 annually, indicating that HIM could alleviate both financial and health burdens on patients [7]

Core Viewpoint - The increasing incidence of cancer among the elderly in China poses a significant challenge for health management, necessitating personalized treatment approaches and early screening initiatives to improve outcomes for this demographic [1][2][10]. Group 1: Cancer Incidence and Characteristics - The proportion of new cancer cases among individuals aged 60 and above in China is 60.7% [1]. - Common malignancies in the elderly include lung cancer and digestive system cancers, accounting for approximately 65% of new cases in this age group [2]. - Factors contributing to cancer in older adults include age-related genetic mutations and the accumulation of carcinogenic factors over time [2][4]. Group 2: Treatment Approaches - There is a tendency among elderly patients to seek unverified remedies or to avoid conventional treatments due to misconceptions about the effects of surgery and chemotherapy [4]. - Personalized treatment plans are essential, taking into account the unique health status and treatment preferences of elderly patients [4]. - Both Western medicine, including targeted therapies and immunotherapy, and traditional Chinese medicine (TCM) play important roles in treating elderly cancer patients [6][8]. Group 3: Quality of Life and Supportive Care - Enhancing the quality of life for cancer patients can lead to improved survival rates [5]. - TCM practices, such as herbal remedies and acupuncture, have been shown to alleviate discomfort during chemotherapy and radiotherapy [8][9]. - Hospitals are developing unique TCM formulations to address specific symptoms associated with cancer treatments [9]. Group 4: Prevention and Early Detection - Early screening and diagnosis are critical for effective cancer management in the elderly [10]. - Initiatives are underway in various regions to provide free cancer screenings for older adults, targeting high-risk populations [10]. - Lifestyle modifications, including balanced nutrition and physical activity, are recommended to enhance the overall health and resilience of elderly individuals [10].

Core Viewpoint - The conference focused on the relationship between depression and insomnia, highlighting the importance of integrated treatment approaches using both traditional Chinese medicine and Western medicine to improve patient outcomes [1][2][4]. Group 1: Conference Overview - The "Chronic Disease Prevention and Treatment in China" conference was held on June 21, combining online and offline formats across Changsha, Wuhan, and Guangzhou, attracting hundreds of experts in mental health [1]. - Professor Zhang Honggeng presented a report on the understanding of "depression and insomnia" from both Chinese and Western medical perspectives, emphasizing the clinical effectiveness of innovative Chinese herbal medicines [1][3]. Group 2: Relationship Between Depression and Insomnia - Depression is characterized by persistent low mood lasting at least two weeks, while insomnia involves difficulty in falling or maintaining sleep for 2-3 weeks, both of which are interrelated [2]. - Approximately 40%-90% of depression patients experience insomnia symptoms, and 71.7% of those treated with antidepressants still have residual insomnia symptoms [2]. - Insomnia increases the risk of developing depression by 183%, anxiety disorders by 223%, and suicide risk by 67%, indicating a bidirectional relationship between the two conditions [2]. Group 3: Treatment Approaches - The conference highlighted the unique advantages of traditional Chinese medicine in identifying and treating depression and insomnia through personalized treatment plans [2][4]. - Innovative Chinese herbal medicines such as "Jieyu Chufan Capsule" and "Yishen Yangxin Anshen Tablet" were discussed for their significant clinical applications in treating different types of depression and insomnia [4]. - The "Jieyu Chufan Capsule" is effective for patients with symptoms like dizziness, chest tightness, and anxiety, while the "Yishen Yangxin Anshen Tablet" is recommended for patients with insomnia due to deficiency syndromes [4]. Group 4: Integration of Treatment Methods - The necessity of combining traditional Chinese and Western medicine for treating depression and insomnia was emphasized, as this approach can enhance treatment efficacy and reduce side effects [4].

Core Viewpoint - The newly released "Guidelines for Percutaneous Coronary Intervention (2025)" recommend the use of Tongxinluo for treating acute coronary syndrome, particularly in patients undergoing interventional treatment, highlighting its efficacy in anti-myocardial ischemia and improving no-reflow and reperfusion injury [1][4]. Group 1: Guidelines Overview - The guidelines were initiated by the Chinese Medical Association's Cardiovascular Disease Branch and the Editorial Committee of the Chinese Journal of Cardiovascular Diseases, with contributions from over 60 cardiovascular experts [3]. - The guidelines provide strict indications and standardized implementation for PCI in China, ensuring patient safety [3]. Group 2: Efficacy of Tongxinluo - Tongxinluo, developed under the theory of collateral disease, has demonstrated significant effects in protecting ischemic tissues, reducing lipid levels, and stabilizing vulnerable plaques [4][5]. - Clinical trials indicate that Tongxinluo can reduce the incidence of no-reflow by 36.6% and lower the 30-day adverse cardiovascular event rate by 36% [5]. Group 3: Efficacy of Qiyuqiangxin - Qiyuqiangxin is recommended for patients with heart failure, particularly those with low blood pressure, as it does not adversely affect blood pressure while improving cardiac function [6]. - Research shows that adding Qiyuqiangxin to standard heart failure treatment can reduce the risk of composite cardiovascular events by 22% [6]. Group 4: Integration of Traditional Chinese Medicine - The guidelines mark a significant breakthrough for Traditional Chinese Medicine (TCM) in coronary intervention, incorporating Tongxinluo and Qiyuqiangxin into treatment recommendations [8]. - Experts emphasize the value of TCM in treating coronary heart disease, showcasing its potential in modern medical practices [8].